{"database": "lobbying", "table": "lobbying_activities", "rows": [[2687911, "8abcfded-18ed-48e9-82b9-4114531a7b38", "Q3", "BROYDRICK & ASSOCIATES", 7268, "TONIX PHARMACEUTICALS", 2021, "third_quarter", "PHA", "Funding new drug for PTSD and COVID 19.", "Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2021-10-19T06:49:26.830000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2687911"], "units": {}, "query_ms": 0.8469759486615658, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}